Related Experiment Video
Updated: May 23, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
[Pacemakers and cardiac resynchronization therapy : recent advances].
Matteo Marchetti1, Mathieu Le Bloa1, Cheryl Teres1
1Service de cardiologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue Medicale Suisse
|May 22, 2026
Summary
Recent innovations in cardiac pacing offer new options for patients. Leadless pacemakers and conduction system pacing, including left bundle branch pacing, provide physiological alternatives to traditional therapies.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Traditional pacemakers face challenges like difficult venous access and infection risk.
- Conventional biventricular pacing for cardiac resynchronization has limitations.
Purpose of the Study:
- To summarize recent advancements in antibradycardia pacing and cardiac resynchronization therapies.
- To highlight novel pacing techniques and their clinical implications.
Main Methods:
- Review of current literature on leadless pacemakers.
- Analysis of physiological pacing techniques, focusing on conduction system pacing.
- Evaluation of evolving concepts in cardiac resynchronization therapy.
Main Results:
- Leadless pacemakers offer a viable alternative for specific patient groups.
- Conduction system pacing, particularly left bundle branch pacing, is now clinically established.
- Conduction system pacing emerges as an alternative to biventricular pacing for cardiac resynchronization.
Conclusions:
- Innovations are expanding treatment options for pacing and resynchronization.
- Leadless and conduction system pacing represent significant progress in cardiac rhythm management.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...